Yahoo
NSE - Delayed Quote INR

Shilpa Medicare Limited (SHILPAMED.NS)

960.00 +24.40 (+2.61%)
At close: October 30 at 3:30:01 PM GMT+5:30
Chart Range Bar
Loading chart for SHILPAMED.NS
  • Previous Close 935.60
  • Open 955.90
  • Bid --
  • Ask --
  • Day's Range 930.30 - 979.80
  • 52 Week Range 259.50 - 1,095.00
  • Volume 903,854
  • Avg. Volume 1,800,274
  • Market Cap (intraday) 187.759B
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) 67.80
  • EPS (TTM) 14.16
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.60 (0.06%)
  • Ex-Dividend Date Sep 4, 2026
  • 1y Target Est 881.25

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.

www.vbshilpa.com

1,241

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

SHILPAMED.NS
199.11%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

SHILPAMED.NS
166.17%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

SHILPAMED.NS
453.06%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

SHILPAMED.NS
230.60%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 4.66B
Earnings --
Profit Margin 0.00%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
1B
2B
3B
4B
0.0%
5.0%
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

635.00 Low
881.25 Average
960.00 Current
1,200.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.67%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    16.83B

  • Net Income Avi to Common (ttm)

    2.97B

  • Diluted EPS (ttm)

    14.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    451.8M

  • Total Debt/Equity (mrq)

    25.46%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: